Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -109.51% is 85% above its 4-year average of -733.67%, near the high end of its 4-year range (-1752.82%–-109.51%).
84.25% above its 12-month average of -695.26%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -32.08%.
RETURN ON ASSETS (ROA)
-109.51%
RETURN ON ASSETS (ROA) AVG TTM
-695.26%
RETURN ON ASSETS (ROA) AVG 3Y
-854.30%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+84.25%
CURRENT VS 3Y AVG
+87.18%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-239.67%
vs the sector median at left
Telomir Pharmaceuticals, Inc. Common Stock
Market Cap
$82.19M
Return on Assets (ROA)
-109.51%
TTM Avg
-695.26%
3Y Avg
-854.30%
5Y Avg
N/A
Market Cap
$82.85M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$82.29M
Return on Assets (ROA)
49.88%
TTM Avg
-47.68%
3Y Avg
-37.92%
5Y Avg
-34.36%
Market Cap
$83.18M
Return on Assets (ROA)
-26.59%
TTM Avg
-23.05%
3Y Avg
-19.50%
5Y Avg
-17.99%
Market Cap
$81.60M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$82.95M
Return on Assets (ROA)
-74.48%
TTM Avg
-208.94%
3Y Avg
-35981.57%
5Y Avg
-24064.76%
Market Cap
$81.69M
Return on Assets (ROA)
-110.64%
TTM Avg
-124.68%
3Y Avg
-93.30%
5Y Avg
-78.61%
Market Cap
$84.19M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$80.25M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $82.19M | -109.51% | -695.26% | -854.30% | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.85M | -107.29% | -60.42% | -51.23% | -39.69% |
| LENSAR Inc (LNSR)vs › | $82.29M | 49.88% | -47.68% | -37.92% | -34.36% |
| MediciNova, Inc. (MNOV)vs › | $83.18M | -26.59% | -23.05% | -19.50% | -17.99% |
| Humacyte, Inc. (HUMA)vs › | $81.60M | -70.05% | -71.47% | -58.80% | -51.13% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.95M | -74.48% | -208.94% | -35981.57% | -24064.76% |
| Nutriband Inc. (NTRB)vs › | $81.69M | -110.64% | -124.68% | -93.30% | -78.61% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.19M | -43.13% | -80.45% | -58.18% | -65.67% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.25M | -74.91% | -50.52% | -40.48% | -70.00% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.24M | -79.38% | 41.63% | -36.06% | -44.84% |
ROA
-109.5%
ROE
-116.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -141.84% |
| 2024-12-31 | -1248.69% |
| 2023-12-31 | -273.83% |
| 2022-12-31 | -1752.82% |
| 2021-12-31 | -251.15% |
